1. Overview
Cytokeratin 19 (CK19) is the smallest cytokeratin, classified as a type I acidic keratin with a molecular weight of approximately 40 kDa. It is generally expressed in the thyroid and is present in both simple and complex epithelium. CK19 commonly shows co-expression with CK7, and controversies exist regarding its expression in malignant versus benign lesions, particularly in thyroid pathology.
Cytokeratin 19 is a cytoplasmic intermediate filament protein encoded by the KRT19 gene and contributes to structural rigidity and multipurpose scaffolding within cells. In several cancers, CK19 is overexpressed and plays a crucial role in tumorigenic transformation. It also acts as a biliary/progenitor cell marker and a tumor stem cell marker.
Additionally, CK19 is involved in the organization of myofibers by linking the contractile apparatus to dystrophin at costameres of striated muscle. Polymorphisms of the CK19 pseudogene have been associated with primary biliary cirrhosis. CK19
2. Symptoms
Cytokeratin 19 itself does not produce symptoms. Its clinical relevance lies in its role as a diagnostic and prognostic marker in epithelial malignancies. Symptoms observed in patients are related to the underlying cancers in which CK19 is expressed, such as thyroid, hepatobiliary, pancreatic, lung, or gastrointestinal malignancies. CK19 expression assists in correlating histopathological findings with clinical presentation, especially in metastatic disease.
3. Causes
Altered or increased CK19 expression is associated with malignant transformation and tumor progression. CK19 is frequently overexpressed in various carcinomas and plays a role in identifying metastasis from carcinoma of unknown primary (CUP).
Cytokeratin 19 expression patterns are useful in differentiating between certain tumor types. CK19 positivity is seen in chordoma, metastatic hepatoid adenocarcinoma, cholangiocarcinoma, and the follicular variant of papillary carcinoma. In contrast, CK19 is typically negative in parachordoma, hepatocellular carcinoma, follicular adenoma, hyaline trabecular adenoma, multinodular goiter with papillary areas, and Graves’ disease, although occasional focal positivity may be observed in some benign lesions.
The marker is also implicated in aggressive tumor biology, particularly when expressed in tumors that otherwise lack typical epithelial differentiation.
4. Risk Factors
CK19 expression is associated with poor prognosis in several malignancies. CK19-positive hepatocellular carcinoma shows more aggressive behavior, with higher rates of early tumor recurrence following hepatectomy or liver transplantation.
In pancreatic endocrine neoplasms, CK19 expression is linked to unfavorable outcomes. CK19 is also considered a poor prognostic factor in non-small cell lung carcinoma (NSCLC). These associations make CK19 a valuable marker for risk stratification and prognostic assessment in oncology.
5. Prevention
There is no direct prevention related to Cytokeratin 19 expression, as it is a biological marker rather than a disease. However, accurate diagnosis depends on proper testing methodology and specimen handling. CK19 detection is performed using immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tissue.
For liquid biopsy applications, RT-PCR is used for highly sensitive detection of CK19-positive cells in blood samples from patients with cancers of the bladder, stomach, skin, cervix, head and neck, pancreas, breast, colon, and gall bladder.
Sample collection for liquid biopsy includes bone marrow aspiration (minimum 2.5 ml) and peripheral blood collected in EDTA tubes. Specimens must be stored and transported at ambient temperature and sent to the laboratory within 8 hours to prevent nucleic acid degradation.
CK19 typically shows cytoplasmic or membranous staining, with variation in intensity and distribution depending on tissue type and cellular characteristics. Internal positive controls are essential and involve identifying known CK19-positive epithelial cells within the tissue. Interpretation of CK19 results should always be correlated with clinical findings and other diagnostic markers to ensure accurate diagnosis and prognosis.
